FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care | Sheppard Mullin Richter & Hampton LLP
The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of...
United States Jackson Women Health Organization Drug Administration Sheppard Mullin Richter Hampton Maryland Us District Court Us Supreme Court
Source: jdsupra.com